FDA Gives Dynatronics Go-Ahead to Market New Laser Probe

SALT LAKE CITY, - Dynatronics Corporation today announced the U.S. Food and Drug Administration has given marketing clearance for the company's new Solaris D890 low-power laser probe. The laser treats muscle and joint pain, including the pain and stiffness associated with arthritis. The Solaris D890 is the second probe designed for use as an accessory to the company's popular new Solaris Series products. The probe is expected to be ready for shipment within 30 to 60 days. "We are thrilled with the FDA's decision to allow us to begin marketing this laser probe," stated Kelvyn H. Cullimore Jr., president of Dynatronics. "Our first attempt to obtain approval for a laser probe was over 20 years ago. That makes this clearance even more satisfying." According to Larry K. Beardall, Dynatronics' executive vice president of marketing and sales, "The new D890 probe will expand the foundation of success our Solaris product line has already achieved. With two decades of clinical research behind them, lasers have been of keen interest to the medical community and have found many applications in medical settings. Hundreds of people around the country have already benefited from light therapy. The results have been remarkable." More information regarding this technology is available at: